Original Article

You have full text access to this OnlineOpen article

Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion

  1. Francesco Bertoldo*,
  2. Serena Pancheri,
  3. Sonia Zenari,
  4. Stefania Boldini,
  5. Benedetta Giovanazzi,
  6. Mirko Zanatta,
  7. Maria Teresa Valenti,
  8. Luca Dalle Carbonare,
  9. Vincenzo Lo Cascio

Article first published online: 18 MAR 2010

DOI: 10.1359/jbmr.090819

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 3, pages 447–454, March 2010

Additional Information

How to Cite

Bertoldo, F., Pancheri, S., Zenari, S., Boldini, S., Giovanazzi, B., Zanatta, M., Valenti, M. T., Carbonare, L. D. and Cascio, V. L. (2010), Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res, 25: 447–454. doi: 10.1359/jbmr.090819

Author Information

  1. Department of Biochemical and Surgical Sciences, University of Verona, Verona, Italy

*c/o Policlinico GB Rossi, P. le LA Scuro, 37134 Verona, Italy.

Publication History

  1. Issue published online: 18 MAR 2010
  2. Article first published online: 18 MAR 2010
  3. Accepted manuscript online: 27 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 27 AUG 2009
  5. Manuscript Revised: 14 AUG 2009
  6. Manuscript Received: 4 MAY 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (199K)

References

  • 1
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007; 40: 1238–1243.
  • 2
    Adami S, Bhalla AK, Dorizzi R, et al. The acute phase response after bisphosphonates administration. Calcif Tissue Int. 1987; 41: 326–331.
  • 3
    Adami S, Zamberlan N. Adverse effect of bisphosphonates: a comparative review. Drug Saf. 1996; 14: 158–170.
  • 4
    Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf. 2007; 30: 755–763.
  • 5
    Schweitzer DH, OOstendorp-van de Ruit M, Van Der Pluijm G, Loewick CW, Papapoulos SE. Interleukin 6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen containing bisphosphonate dimethyl aminohydroxypropylidene bisphosphonate. J Bone Miner Res. 1995; 10: 956–962.
    Direct Link:
  • 6
    Thiebaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997; 61: 386–392.
  • 7
    Ceciliani F, Giordano A, Spagnolo V. The systemic reaction during inflammation: the acute-phase proteins. Protein Pept Lett. 2002; 9: 211–223.
  • 8
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006; 12: 6222–6230 S.
  • 9
    Galluzzo S, Santini D, Vincenzi B, et al. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets. 2007; 11: 941–954.
  • 10
    Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobispohsphonates is inhibited by statins. Clin Exp Immunol. 2005; 139: 101–111.
    Direct Link:
  • 11
    Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced γδ T cell proliferation and activation in vitro. J Bone Miner Res. 2004; 19: 278–288.
    Direct Link:
  • 12
    Chen L, Cencioni MT, Angelini DF, Borsellino G, Battistini L, Brosnan CF. Transcriptional profiling of γδ T cells identifies a role for vitamin D in the immunoregulation of the Vγ9Vδ2 response to phosphonate-containing ligands. J Immunol. 2005; 174: 6144–6152.
  • 13
    Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase response. J Oncol Pharm Pract. 2007; 13: 223–229.
  • 14
    Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733–759.
  • 15
    Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357: 266–281.
  • 16
    Black DM, Delmas PD, Eastell R, et al. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809–1822.
  • 17
    Bettica P, Bevilacqua M, Vago T, Norbiato G. High prevalence of hypovitaminosis D among free-living post-menopausal women referred to an opsteoporosis outpatient clinic in northern Italy for initial screening. Osteoporosis Int. 1999; 9: 226–229.
  • 18
    Carnevale V, Modoni S, Pileri M, et al. Longitudinal evaluation of vitamin D status in healthy subjects from southern Italy: seasonal and gender differences. Osteoporosis Int. 2001; 12: 1026–1030.
  • 19
    Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357: 1799–1809.
  • 20
    Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006; 92: 4–8.
  • 21
    Orwoll E, Nielson CM, Marshall LM, et al. Vitamin D deficiency in older men. J Clin Endocrinol Metab. 2009; 94: 1214–1222.
  • 22
    Snijder MB, van Dam RM, Visser M, et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab. 2005; 90: 4119–4123.
  • 23
    Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009; 94: 26–34.
  • 24
    Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet. 1994; 343: 435–439.
  • 25
    Crawford VL, Sweeney O, Coyle PV, Halliday IM, Stout RW. The relationship between elevated fibrinogen and markers of infection: a comparison of seasonal cycles. Q J Med. 2000; 93: 745–750.
  • 26
    Ross RD, Frengley JD, Mion LC, Kushner I. Elevated C-reactive protein in older people. J Am Geriatr Soc. 1992; 40: 104–105.
  • 27
    Passeri G, Pini G, Troiano L, et al. Low vitamin D status, high bone turnover, and bone fractures in centenarians. J Clin Endocrinol Metab. 2003; 88: 5109–5115.
  • 28
    Rothenbacher D, Hoffmeister A, Brenner H, Koenig W. Physical activity, coronary heart disease, and inflammatory response. Arch Intern Med. 2003; 163: 1200–1205.
  • 29
    Reuben DB, Judd-Hamilton L, Harris TB, Seeman TE. The associations between physical activity and inflammatory markers in high functioning older persons: McArthur Studies of Successful Aging. J Am Geriatr Soc. 2003; 51: 1125–1130.
    Direct Link:
  • 30
    Koenig W, Sund M, Doring A, Ernst E. Leisure time physical activity but not work related physical activity is associated with decreased plasma viscosity: results from a large population sample. Circulation. 1997; 95: 335–341.
  • 31
    Assanelli D, Bersatti F, Ferrari R, et al. Effect of leisure time and working activity on principal risk factors and relative interactions in active middle-aged men. Coronary Artery Dis. 1999; 10: 1–7.
  • 32
    Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study. Arterioscler Thromb Vasc Biol. 2000; 20: 271–279.
  • 33
    Van den Berghe G, Van Roosbroek D, Vanhove P, Wouters PJ, De Pourcq L, Bouillon R. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab. 2003; 88: 4623–4632.
  • 34
    Pasco JA, Henry MJ, Nicholson GC, Brennan SL, Kotowicz MA. Behavioural and physical characteristics associated with vitamin D status in women. Bone. 2009; 44: 1085–1891.
  • 35
    Penna G, Roncari A, Armuchastegui S, et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood. 2005; 106: 3490–3497.
  • 36
    Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute phase response of human hepatocytes: regulation of acute phase protein synthesis by interleukin 6. Hepatology. 1990; 12: 1179–1186.
    Direct Link:
  • 37
    Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin 6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989; 242: 237–239.
  • 38
    Mitnik MA, Grey A, Masiukiewicz U, et al. Parathyroid hormone induces hepatic production of bioactive interleukin 6 and its soluble receptor. Am J Physiol Endocrinol Metab. 2001; 280: E405–412.
  • 39
    Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol. 2004; 89-90: 611–614.
  • 40
    Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol. 2008; 624: 55–71.
  • 41
    Bischoff Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentration of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006; 84: 18–28.
  • 42
    McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007; 41: 122–128.
  • 43
    Generali D, Dovio A, Tampellini M, et al. Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. Br J Cancer. 2008; 98: 1753–1758.
  • 44
    Davies M, Heys SE, Selby PL, Berry JL, Mawer EB. Increased catabolism of 25-hydroxyvitamin D in patients with partial gastrectomy and elevated 1,25-dihydroxyvitamin D levels: implications for metabolic bone disease. J Clin Endocrinol Metab. 1997; 82: 209–212.
  • 45
    Clements MR, Jhonson L, Fraser DR. A new mechanism for induced vitamin D deficiency in calcium deprivation. Nature. 1987; 325: 62–65.
  • 46
    Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocana A, Stewart AF. Direct comparison of sustained infusion of human parathyroid hormone related protein (1-36) [hPTHrP-(1-36)] versus hPTH(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab. 2003; 88: 1603–1609.
  • 47
    Burnett-Bowie SA, Henao MP, Dere ME, Lee H, Leder BZ. Effects of hPTH (1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D and FGF23 levels in healthy men. J Bone Miner Res. 2009; (DOI: 10.1359/jbmr.090406.).
    Direct Link:
  • 48
    Cosman F, Nieves J, Morgan D, et al. Parathyroid hormone secretory response to EDTA-induced hypocalcemia in black and white premenopausal women. Calcif Tissue Int. 1999; 65: 257–261.
  • 49
    Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008; 4: 80–90.
  • 50
    Dieli F, Gebbia N, Poccia F, et al. Induction of gd T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003; 102: 2310–2311.
  • 51
    Santini D, Martini F, Fratto ME, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother. 2009; 58: 31–38.
  • 52
    Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long term extension. Clin Rheumatol. 2008; 27: 955–960.
  • 53
    Srivastava T, Haney CJ, Alon US. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res. 2009; 24: 334–337.
    Direct Link:
  • 54
    Hypponen E, Turner S, Cumberland P, Power C, Gibb I. Serum 25 hydroxyvitamin D measurement in a large population survey with statistical harmonization of assay variation to an international standard. J Clin Endocrinol Metab. 2007; 92: 4615–4622.
  • 55
    Lips P, Chapuy MC, Dawson-Hughes B, Pols HA, Holick MF. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int. 1999; 9: 394–397.
  • 56
    Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab. 2004; 89: 3152–3157.
View Full Article (HTML) Get PDF (199K)